1-methyl-2-benzoxypropylamine | 201044-00-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-2-benzoxypropylamine
• 英文别名: 3-phenylmethoxybutan-2-amine
• CAS: 201044-00-0
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: ISZJXQFTICREBY-UHFFFAOYSA-N

物化性质

• 沸点：
  263.5±15.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-methyl-2-benzoxypropylazide 、 水 在 sodium hydroxide 作用下， 以92%的产率得到1-methyl-2-benzoxypropylamine
  参考文献：
  名称：

  IL-8 receptor antagonists

  摘要：

  这项发明涉及使用式(I)和(II)的苯基脲类化合物治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态。其中(I)和(II)的变量在此定义。

  公开号：

  US06133319A1

文献信息

• Estrogen receptor-modulating compounds
  申请人：Radius Pharmaceuticals, Inc.

  公开号：US11384068B2

  公开（公告）日：2022-07-12

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述的化合物是雌激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物，以及单独或与其他化合物结合使用此类雌激素受体调节剂治疗介导或依赖于雌激素受体的疾病或病症的方法。
• ESTROGEN RECEPTOR-MODULATING COMPOUNDS
  申请人：Radius Pharmaceuticals, Inc.

  公开号：US20200347032A1

  公开（公告）日：2020-11-05

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
• COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF
  申请人：Korea Research Institute of Chemical Technology

  公开号：US20210047277A1

  公开（公告）日：2021-02-18

  The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
• US6133319A
  申请人：——

  公开号：US6133319A

  公开（公告）日：2000-10-17
• [EN] HETEROCYCLIC INHIBITORS OF ATR KINASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE ATR
  申请人：UNIV TEXAS

  公开号：WO2019178590A1

  公开（公告）日：2019-09-19

  The present disclosure relates to heterocyclic compounds and methods which inhibit ATR kinase to treat or prevent cancer. Certain compounds disclosed herein may possess useful ATR kinase inhibiting activity, and may be used in the treatment or prophylaxis of a disease or condition in which ATR kinase plays an active role.